HALO
Halozyme Therapeutics, Inc. · Healthcare
Director Matthew L. Posard sold $2.0M of Halozyme Therapeutics, Inc.
Sold$2,046,581
$107.74Price
18,996Shares
−24%Stake
What HALO did after the filing
- The stock from Fri, Sep 18 open, $109.72
- +0.1%
- S&P 500, same days
- +1.7%
14 of 30 trading days so far, to the Oct 8 close.
Traded Wed, Sep 16. Filed Thu, Sep 17, 5:19 PM ET, after the close. Returns use the Sep 18 open and the Oct 8 close. Not investment advice.